Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agenus reports robust Q4 earnings, advances immuno-oncology pipeline

Agenus showcased strong financials, progress in immuno-oncology pipeline, and durable responses in various cancers
Strategic partnerships and innovative R&D capabilities position the company well for future growth and development
Challenges in enrollment, differentiation, and managing immune-related toxicities are being actively addressed for continued success

Agenus (AGEN) reports progress in cancer treatment programs

Agenus (AGEN) showcased strong progress in its cancer treatment programs, with notable response rates and Fast Track Designation for a promising combination therapy.
While financials remained stable, the company faces challenges in maintaining response rates and successful study enrollments, requiring effective regulatory navigation and communication strategies.
Opportunities for Agenus include presenting at ASCO, expanding development programs, and attracting partnerships to drive further advancements in oncology treatments.

Agenus reports positive trial outcomes and strong regulatory strategy

Agenus is making significant progress in cancer treatment with positive trial outcomes and a strong regulatory strategy.
The company's commitment to innovation, patient quality of life, and managing side effects positions them well for future success.
Challenges include addressing analyst inquiries, enrollment in studies, and managing toxicities, but opportunities exist in partnerships and targeted treatment approaches.

Agenus reports robust earnings, eyes strategic partnerships for growth

Agenus Inc. demonstrated strong financial performance and progress in its BOT/BAL program.
While facing challenges in trial enrollment and funding, the company is focused on strategic partnerships.
Opportunities lie in upcoming data disclosures, potential BLA submissions, and product launches.

Agenus reports Q1 2024 financials, progresses BOT/BAL program for growth

Agenus navigates financial challenges with a focus on advancing the BOT/BAL program towards commercialization. Despite losses, the company's strategic initiatives position it for potential growth opportunities through milestone achievements and market expansion.

Agenus (AGEN) reports Q3 loss, advances cancer therapy innovations

Agenus (AGEN) is navigating financial challenges with a focus on advancing transformative cancer therapy and strategic partnerships.
Despite a net loss of $67 million, progress in BOT/BAL development and strategic initiatives position Agenus for future growth.
Opportunities in upcoming clinical studies and data readouts in 2025 underscore the company's commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Agenus Inc. (AGEN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Can Join The Securities Fraud Investigation By The Schall Law Firm

AGEN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Agenus Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Levi & Korsinsky Reminds Agenus Investors of the Ongoing Investigation into Potential Violations of Securities Laws – AGEN

Levi & Korsinsky Reminds Agenus Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGEN

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

AGEN STOCK ALERT: Levi & Korsinsky Notifies Agenus Inc. Investors of an Ongoing Investigation

LOS ANGELES , July 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ: AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm

Investors who Lost Money on Agenus Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AGEN

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about Securities Fraud Investigation - AGEN

NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Levi & Korsinsky Announces an Investigation on Behalf of Agenus Inc. (AGEN) Shareholders Who May Have Been Affected by Fraud

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Have The Chance To Participate In The Securities Fraud Probe By The Schall Law Firm

AGEN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Agenus Inc.

Thursday, Agenus Inc. AGEN announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with relapsed/refractory microsatellite-stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity

The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.

Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data

NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!

Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "Herpes Simplex Virus Infections - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Herpes Simplex Virus Infections is estimated at US$5.0 Billion in 2023 and is projected to reach US$6.6 Billion by 2030, growing at a CAGR of 4.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the HSV infections treatment market is driven by several factors. Technological advancements in antiviral drug formulations are enhancing the effectiveness and convenience of treatments, making them more accessible to a broader patient population. The rising prevalence of HSV infections worldwide, coupled with increasing awareness and diagnosis rates, is expanding the demand for effective management solutions. Consumer behavior trends towards proactive health management and the demand for convenient, over-the-counter treatment options are also contributing to market growth.

$6.6 Bn Herpes Simplex Virus Infections Markets - Global Strategic Business Report to 2030 with Coverage of 10+ Major Players Including Admedus, Agenus, and Aicuris Anti-infective Cures

NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm!

Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA's) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy.

Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy

Agenus (NASDAQ: AGEN ) stock is falling hard on Thursday after the clinical-stage biotechnology company provided results from a Phase 2 clinical trial of botensilimab and balstilimab as a colorectal cancer treatment. Specfically, the company met with the Food and Drug Administration (FDA) to conduct an end-of-Phase 2 meeting.

Why Is Agenus (AGEN) Stock Down 55% Today?

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (N.

Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany. Dr. Pashtoon Kasi, the originator of this groundbreaking study,.

News for Agenus Stock (AGEN)